Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Apr

Today In Oncology

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings

Invitation to Colonoscopy vs Fecal Immunochemical Test Screening for Colorectal Cancer

Study Illuminates Disparities in Treatment Survival in Metastatic Pancreatic Ductal Adenocarcinoma

American Cancer Society Launches CEO Search

Frailty Following Chemotherapy May Be Linked to Poorer Survival in Older Women With Breast Cancer